Antimalarial Drug Discovery and Development Strategies

Recent decades have seen an integrated framework combining phenotypic screening and target-based approaches to enrich the antimalarial pipeline. Phenotypic assays across multiple parasite life cycle stages have revealed novel chemotypes, while structural biology and high-throughput screening accelerate target-based lead identification. Hit-to-lead campaigns employ medicinal chemistry and pharmacokinetic profiling to optimise potency, selectivity and bioavailability. Concurrently, target candidate and product profiles guide the selection of compounds with multistage efficacy, transmission-blocking potential and single-dose regimens. Innovations in chemical proteomics and genetic validation underpin target deconvolution, enabling rational design against essential parasite proteins. These strategies address the global threat of drug resistance by diversifying mechanisms of action and fostering combination therapies. Collectively, this multi-pronged paradigm drives progress towards safer, more effective treatments deployable in varied endemic settings, paving the way for malaria control and eventual eradication.

Research from Nature Portfolio

Recent studies have identified novel mechanisms targeting essential parasite processes. A new series of aryl amino acetamides selectively inhibits ring-stage development by binding to the lipid-transfer protein PfSTART1, impeding parasitophorous vacuole membrane expansion and blocking transmission to the mosquito vector. Earlier seminal work on pyrazoleamide compounds revealed rapid disruption of sodium homeostasis via inhibition of the plasma-membrane Na+-ATPase PfATP4, demonstrating a chemically distinct multistage mode of action and rapid parasite clearance in vivo. These findings underscore the value of mechanistic target identification and the potential for multistage efficacy in next-generation antimalarial agents.

Antimalarial Drug Discovery and Development Strategies publication trend

The graph below shows the total number of articles in antimalarial drug discovery and development strategies across all publications each year (not limited to Nature Index journals).

Technical terms

PfSTART1: Lipid-transfer protein in Plasmodium falciparum required for parasitophorous vacuole membrane expansion during the ring stage.

PfATP4: Parasite plasma-membrane sodium-ATPase governing intracellular Na+ homeostasis and targeted by distinct chemical classes.

Chemo-proteomics: Chemical biology methods combining affinity probes and mass spectrometry to identify and validate drug–target interactions.

References

1. Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1. Nature Communications (2024).
2. Chemo‐proteomics in antimalarial target identification and engagement. Medicinal Research Reviews (2023).
3. The past, present and future of anti-malarial medicines. Malaria Journal (2019).
4. Designing the next generation of medicines for malaria control and eradication. Malaria Journal (2013).
5. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nature Communications (2014).